Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2026)

Corcept Therapeutics (CORT) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $15.3 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 7.57% year-over-year to $15.3 million; the TTM value through Mar 2026 reached $15.3 million, up 7.57%, while the annual FY2025 figure was $15.2 million, 7.75% up from the prior year.
  • Other Non-Current Liabilities hit $15.3 million in Q1 2026 for Corcept Therapeutics, up from $15.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $15.7 million in Q2 2025 and bottomed at $2.5 million in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $11.1 million, with a median of $10.9 million recorded in 2024.
  • Year-over-year, Other Non-Current Liabilities soared 2124.21% in 2022 and then increased 7.57% in 2026.
  • Corcept Therapeutics' Other Non-Current Liabilities stood at $9.1 million in 2022, then increased by 13.3% to $10.3 million in 2023, then soared by 36.64% to $14.1 million in 2024, then increased by 7.75% to $15.2 million in 2025, then increased by 1.03% to $15.3 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $15.3 million, $15.2 million, and $14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.